![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, May 29, 2020 6:42:03 AM
Andrew Sloan, MD, who holds the Peter D. Cristal Chair in Neurosurgical Oncology and serves as Director of both the Brain Tumor and Neuro-Oncology Center, and the Center of Excellence for Translational Neuro-Oncology at UH Seidman Cancer Center and UH Cleveland Medical Center; Professor of Neurosurgery, Case Western Reserve University School of Medicine, has conducted clinical trials with 5-ALA for almost a decade via his own FDA-approved Investigational New Drug clinical trial. The drug, which has been the standard of care in most of Europe for many years, causes cancer to fluoresce, which helps surgeons better identify the edges of the tumor and safely remove more of the mass than using traditional visualization methods.
“The goal is maximal safe extraction of the solid portion of the tumor,” Dr. Sloan explains. “With gliomas, you can never take every single cell out, but we know that 99 percent of the tumor is contained in the solid mass. So being able to clearly visualize those boundaries is a real advantage.”
Nearly 16,000 Americans are diagnosed with malignant gliomas each year. Most live fewer than 2 years after diagnosis, but more complete removal of the tumor can extend that.
“It’s very clear that patients do better and survive longer if you can take out as much of the tumor as possible, and any tool that helps you do that helps improve patient outcomes,” Dr. Sloan says.
In fact, patients whose tumors are removed with 5-ALA typically survive twice as long as others, he adds.
LIGHTING THE WAY
Dr. Sloan says his research protocol for using the drug is very similar to what was approved by the FDA last year. Thanks to that approval, he now uses 5-ALA in virtually every applicable case.
Resection using motor-mapping and 5-ALA
Patients don’t notice much of a difference other than taking the drug by mouth before surgery. Most healthy tissue can metabolize the drug to hemoglobin, a component of blood. However, cancer cells cannot fully process the drug, which accumulates as Protoporphyrin IX and causes malignant brain tumors to glow or fluorescence as pink under blue light. The surgeon uses a specially modified surgical microscope to turn blue light on and off during the procedure to guide the excision. This process only adds a few minutes to the overall surgical time.
“To a large extent, the invading edge of the tumor looks a lot like normal brain,” Dr. Sloan says. “It can be very hard to tell the difference, especially toward the end of the operation when the brain is starting to sag and shift, and the pre-op stereotactic imaging is no longer as precise as it was at the beginning of the case.
“By making the tumor turn pink under the blue light, it makes it easier for the surgeon to know when he or she has the tumor’s boundary. Once you hit that boundary and it’s no longer pink, then you know you need to stop or you risk damaging healthy brain.”
This approach, which Dr. Sloan predicted will eventually become standard of care nationwide, is approved for treatment of Grades 3 and 4 gliomas. He and his colleagues are exploring other indications for it, as well, he says.
https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2019/01/giving-surgeons-an-edge
So it's clear that employment of 5-ALA is going to increase around the world.
If you can take it literally that 5-ALA doubles survival, then if I was struck down with GBM, I would want to have my surgery at somewhere that was 5-ALA equipped!
If the hold was about this issue, then better it was addressed and hopefully resolved early, and won't be any sort of stumbling block when it comes to regulatory submission.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM